These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 3088217)

  • 1. Effect of hypoglycaemia, TRH and levodopa on plasma growth hormone, prolactin, thyrotropin and cortisol in Parkinson's disease before and during therapy.
    Vogel HP; Ketsche R
    J Neurol; 1986 Jun; 233(3):149-52. PubMed ID: 3088217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thyrotrophin and prolactin responses to thyrotrophin-releasing hormone in patients with Parkinson's disease.
    Martinez-Campos A; Giovannini P; Novelli A; Cocchi D; Caraceni T; Müller EE
    Acta Endocrinol (Copenh); 1982 Mar; 99(3):344-51. PubMed ID: 6803485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth hormone and prolactin stimulation by Madopar in Parkinson's disease.
    Martinez-Campos A; Giovannini P; Parati E; Novelli A; Caraceni T; Müller EE
    J Neurol Neurosurg Psychiatry; 1981 Dec; 44(12):1116-23. PubMed ID: 7334406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypothalamo-pituitary function and dopamine dependence in untreated parkinsonian patients.
    Cusimano G; Capriani C; Bonifati V; Meco G
    Acta Neurol Scand; 1991 Mar; 83(3):145-50. PubMed ID: 1903236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Neuroendocrine correlations in the pathogenesis and pathology of Parkinson disease].
    Pinessi L; Sabbatini F; De Mattei M; Gentile S
    Minerva Med; 1984 Nov; 75(42):2539-42. PubMed ID: 6096765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Patients with Parkinson disease: functional analysis of dopamine receptors by bromocriptine- thyrotropin-releasing hormone test].
    Díaz F; Liberman C; Chariá P
    Rev Med Chil; 1991 Mar; 119(3):252-7. PubMed ID: 1842116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypothalamic-pituitary function in diverse hyperprolactinemic states.
    Boyar RM; Kapen S; Finkelstein JW; Perlow M; Sassin JF; Fukushima DK; Weitzman ED; Hellman L
    J Clin Invest; 1974 Jun; 53(6):1588-98. PubMed ID: 4208470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of levodopa on thyroid function and prolactin release. A study in patients with Parkinson's disease.
    Lavin PJ; Gawel MJ; Das PK; Alaghband-Zadeh J; Rose FC
    Arch Neurol; 1981 Dec; 38(12):759-60. PubMed ID: 6797388
    [No Abstract]   [Full Text] [Related]  

  • 9. [Studies on the hypothalamic-pituitary dopaminergic system in Parkinson's disease and spinocerebellar degeneration. Response to TRH and sulpiride].
    Joshita Y
    Nihon Naika Gakkai Zasshi; 1987 Jan; 76(1):59-66. PubMed ID: 3106541
    [No Abstract]   [Full Text] [Related]  

  • 10. Tuberoinfundibular dopaminergic function in Parkinson's disease.
    Franceschi M; Camerlingo M; Perego L; Bottacchi E; Truci G; Mamoli A
    Eur Neurol; 1988; 28(3):117-9. PubMed ID: 3133213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissociation of thyrotropin and prolactin responsiveness to thyrotropin releasing hormone stimulation in L-dopa treated parkinsonian patients.
    Rabey JM; Vardi Y; Ravid R; Ayalon D
    Horm Res; 1981; 15(2):78-87. PubMed ID: 6799381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Madopar in the treatment of paralysis agitans: II. TRH activation test, EMG examination and HVA level in cerebrospinal fluid before and after treatment].
    Liu DK
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1980 Apr; 13(4):223-6. PubMed ID: 6790255
    [No Abstract]   [Full Text] [Related]  

  • 13. Hypothalamic dysfunction in Parkinson's disease patients.
    Otake K; Oiso Y; Mitsuma T; Hirooka Y; Adachi K
    Acta Med Hung; 1994; 50(1-2):3-13. PubMed ID: 7638039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic evaluation of growth hormone (GH) and prolactin (hPRL) secretion in active acromegaly with high and low GH output.
    Tolis G; Kovacs L; Friesen H; Martin JB
    Acta Endocrinol (Copenh); 1975 Feb; 78(2):251-7. PubMed ID: 803748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's disease.
    Ruggieri S; Falaschi P; Baldassarre M; D'Urso R; De Giorgio G; Rocco A; Agnoli A
    Neuropsychobiology; 1982; 8(2):102-8. PubMed ID: 7070643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolactin secretion in Parkinson disease.
    Eisler T; Thorner MO; MacLeod RM; Kaiser DL; Calne DB
    Neurology; 1981 Oct; 31(10):1356-9. PubMed ID: 6810204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of long term erythropoietin therapy on the hypothalamic-pituitary-thyroid axis in patients undergoing capd.
    Tokgöz B; Utaş C; Doğukan A; Oymak O; Keleştimur F
    Ren Fail; 2002 May; 24(3):315-23. PubMed ID: 12166698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of TRH on TSH and prolactin levels in affective disorders.
    Kjellman BF; Ljunggren JG; Beck-Friis J; Wetterberg L
    Psychiatry Res; 1985 Apr; 14(4):353-63. PubMed ID: 3927333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Function of dopamine receptors in young-onset Parkinson's disease: prolactin response.
    Kostic VS; Marinkovic Z; Filipovic S; Momcilovic D
    Mov Disord; 1993 Apr; 8(2):227-9. PubMed ID: 8474497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disturbances in the hypothalamo-pituitary-adrenal and other neuroendocrine axes in bulimia.
    Fichter MM; Pirke KM; Pöllinger J; Wolfram G; Brunner E
    Biol Psychiatry; 1990 May; 27(9):1021-37. PubMed ID: 2110485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.